- Report
- November 2023
- 150 Pages
Global
From €4493EUR$4,850USD£3,749GBP
- Report
- October 2025
- 160 Pages
Global
From €2927EUR$3,160USD£2,443GBP
€3659EUR$3,950USD£3,053GBP
- Report
- October 2025
- 160 Pages
Global
From €2927EUR$3,160USD£2,443GBP
€3659EUR$3,950USD£3,053GBP
- Report
- October 2025
- 95 Pages
Global
From €4168EUR$4,500USD£3,479GBP
- Report
- July 2025
- 134 Pages
Global
From €4307EUR$4,650USD£3,595GBP
- Report
- May 2025
- 130 Pages
Global
From €4493EUR$4,850USD£3,749GBP
- Drug Pipelines
- July 2023
- 139 Pages
Global
From €13890EUR$14,995USD£11,591GBP
- Report
- February 2024
- 88 Pages
Global
From €3500EUR$4,048USD£3,023GBP
- Report
- January 2025
- 132 Pages
Global
From €880EUR$950USD£734GBP
- Report
- November 2025
- 132 Pages
Global
From €880EUR$950USD£734GBP
- Report
- April 2024
- 132 Pages
Global
From €880EUR$950USD£734GBP
- Report
- April 2024
- 132 Pages
Global
From €880EUR$950USD£734GBP
- Report
- December 2022
- 42 Pages
Global
From €3242EUR$3,500USD£2,706GBP

The Parkinson Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Parkinson's Disease is a progressive neurological disorder that affects movement, and is caused by a lack of dopamine in the brain. Parkinson Drugs are used to treat the symptoms of the disease, and can include levodopa, dopamine agonists, monoamine oxidase inhibitors, and catechol-O-methyltransferase inhibitors. These drugs can help to improve motor function, reduce tremors, and improve quality of life.
The Parkinson Drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include AbbVie, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more